Gland Pharma has received approval from the US Food and Drug Administration (USFDA) for its generic version of Angiotensin II Acetate Injection 2.5 mg/mL, a medication used to manage blood pressure in critically ill patients. The Hyderabad-based pharmaceutical company has been granted "First-to-File" status, securing 180 days of exclusivity in the competitive US market. This move enhances Gland Pharma's footprint in the US, where the reference drug Giapreza generated approximately USD 58 million in sales over the last year.